249 related articles for article (PubMed ID: 27124905)
1. Identification of Factors Affecting the Success of Next-Generation Sequencing Testing in Solid Tumors.
Goswami RS; Luthra R; Singh RR; Patel KP; Routbort MJ; Aldape KD; Yao H; Dang HD; Barkoh BA; Manekia J; Medeiros LJ; Roy-Chowdhuri S; Stewart J; Broaddus RR; Chen H
Am J Clin Pathol; 2016 Feb; 145(2):222-37. PubMed ID: 27124905
[TBL] [Abstract][Full Text] [Related]
2. Factors affecting the success of next-generation sequencing in cytology specimens.
Roy-Chowdhuri S; Goswami RS; Chen H; Patel KP; Routbort MJ; Singh RR; Broaddus RR; Barkoh BA; Manekia J; Yao H; Medeiros LJ; Staerkel G; Luthra R; Stewart J
Cancer Cytopathol; 2015 Nov; 123(11):659-68. PubMed ID: 26230354
[TBL] [Abstract][Full Text] [Related]
3. Comparison of cytocentrifugation supernatant fluid and formalin-fixed paraffin-embedded tissue for targeted next-generation sequencing.
Janaki N; Harbhajanka A; Michael CW; Bomeisl P; Wasman J; Atchley M; Miskiewicz K; Alouani D; Sadri N
Cancer Cytopathol; 2019 May; 127(5):297-305. PubMed ID: 30933438
[TBL] [Abstract][Full Text] [Related]
4. Factors Impacting Clinically Relevant RNA Fusion Assays Using Next-Generation Sequencing.
Ramani NS; Patel KP; Routbort MJ; Alvarez H; Broaddus R; Chen H; Rashid A; Lazar A; Lucas FAS; Yao H; Manekia J; Dang H; Barkoh BA; Medeiros LJ; Luthra R; Roy-Chowdhuri S
Arch Pathol Lab Med; 2021 Nov; 145(11):1405-1412. PubMed ID: 33493304
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of an integrated clinical workflow for targeted next-generation sequencing of low-quality tumor DNA using a 51-gene enrichment panel.
Choudhary A; Mambo E; Sanford T; Boedigheimer M; Twomey B; Califano J; Hadd A; Oliner KS; Beaudenon S; Latham GJ; Adai AT
BMC Med Genomics; 2014 Nov; 7():62. PubMed ID: 25395014
[TBL] [Abstract][Full Text] [Related]
6. Targeted Next Generation Sequencing as a Reliable Diagnostic Assay for the Detection of Somatic Mutations in Tumours Using Minimal DNA Amounts from Formalin Fixed Paraffin Embedded Material.
de Leng WW; Gadellaa-van Hooijdonk CG; Barendregt-Smouter FA; Koudijs MJ; Nijman I; Hinrichs JW; Cuppen E; van Lieshout S; Loberg RD; de Jonge M; Voest EE; de Weger RA; Steeghs N; Langenberg MH; Sleijfer S; Willems SM; Lolkema MP
PLoS One; 2016; 11(2):e0149405. PubMed ID: 26919633
[TBL] [Abstract][Full Text] [Related]
7. Profiling cancer gene mutations in clinical formalin-fixed, paraffin-embedded colorectal tumor specimens using targeted next-generation sequencing.
Zhang L; Chen L; Sah S; Latham GJ; Patel R; Song Q; Koeppen H; Tam R; Schleifman E; Mashhedi H; Chalasani S; Fu L; Sumiyoshi T; Raja R; Forrest W; Hampton GM; Lackner MR; Hegde P; Jia S
Oncologist; 2014 Apr; 19(4):336-43. PubMed ID: 24664487
[TBL] [Abstract][Full Text] [Related]
8. Versatile ion S5XL sequencer for targeted next generation sequencing of solid tumors in a clinical laboratory.
Mehrotra M; Duose DY; Singh RR; Barkoh BA; Manekia J; Harmon MA; Patel KP; Routbort MJ; Medeiros LJ; Wistuba II; Luthra R
PLoS One; 2017; 12(8):e0181968. PubMed ID: 28767674
[TBL] [Abstract][Full Text] [Related]
9. Validation of the Oncomine
Williams HL; Walsh K; Diamond A; Oniscu A; Deans ZC
Virchows Arch; 2018 Oct; 473(4):489-503. PubMed ID: 30105577
[TBL] [Abstract][Full Text] [Related]
10. Amplicon-Based Targeted Next-Generation Sequencing of Formalin-Fixed, Paraffin-Embedded Tissue.
Strengman E; Barendrecht-Smouter FAS; de Voijs C; de Vree P; Nijman IJ; de Leng WWJ
Methods Mol Biol; 2019; 1908():1-17. PubMed ID: 30649717
[TBL] [Abstract][Full Text] [Related]
11. Young investigator challenge: Can the Ion AmpliSeq Cancer Hotspot Panel v2 be used for next-generation sequencing of thyroid FNA samples?
Bellevicine C; Sgariglia R; Malapelle U; Vigliar E; Nacchio M; Ciancia G; Eszlinger M; Paschke R; Troncone G
Cancer Cytopathol; 2016 Nov; 124(11):776-784. PubMed ID: 27717198
[TBL] [Abstract][Full Text] [Related]
12. Pre-clinical validation of a next generation sequencing testing panel.
Lüsebrink J; Pieper M; Tillmann RL; Brockmann M; Schildgen O; Schildgen V
Exp Mol Pathol; 2018 Jun; 104(3):170-174. PubMed ID: 29641993
[TBL] [Abstract][Full Text] [Related]
13. Utilization of cytology smears improves success rates of RNA-based next-generation sequencing gene fusion assays for clinically relevant predictive biomarkers.
Ramani NS; Chen H; Broaddus RR; Lazar AJ; Luthra R; Medeiros LJ; Patel KP; Rashid A; Routbort MJ; Stewart J; Tang Z; Bassett R; Manekia J; Barkoh BA; Dang H; Roy-Chowdhuri S
Cancer Cytopathol; 2021 May; 129(5):374-382. PubMed ID: 33119213
[TBL] [Abstract][Full Text] [Related]
14. Using "residual" FNA rinse and body fluid specimens for next-generation sequencing: An institutional experience.
Wei S; Lieberman D; Morrissette JJ; Baloch ZW; Roth DB; McGrath C
Cancer Cytopathol; 2016 May; 124(5):324-9. PubMed ID: 26682952
[TBL] [Abstract][Full Text] [Related]
15. Multicenter validation of cancer gene panel-based next-generation sequencing for translational research and molecular diagnostics.
Hirsch B; Endris V; Lassmann S; Weichert W; Pfarr N; Schirmacher P; Kovaleva V; Werner M; Bonzheim I; Fend F; Sperveslage J; Kaulich K; Zacher A; Reifenberger G; Köhrer K; Stepanow S; Lerke S; Mayr T; Aust DE; Baretton G; Weidner S; Jung A; Kirchner T; Hansmann ML; Burbat L; von der Wall E; Dietel M; Hummel M
Virchows Arch; 2018 Apr; 472(4):557-565. PubMed ID: 29374318
[TBL] [Abstract][Full Text] [Related]
16. A Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors.
Luthra R; Patel KP; Routbort MJ; Broaddus RR; Yau J; Simien C; Chen W; Hatfield DZ; Medeiros LJ; Singh RR
J Mol Diagn; 2017 Mar; 19(2):255-264. PubMed ID: 28017569
[TBL] [Abstract][Full Text] [Related]
17. Salvaging the supernatant: next generation cytopathology for solid tumor mutation profiling.
Roy-Chowdhuri S; Mehrotra M; Bolivar AM; Kanagal-Shamanna R; Barkoh BA; Hannigan B; Zalles S; Ye W; Duose D; Broaddus R; Staerkel G; Wistuba I; Medeiros LJ; Luthra R
Mod Pathol; 2018 Jul; 31(7):1036-1045. PubMed ID: 29463880
[TBL] [Abstract][Full Text] [Related]
18. Comparison of next-generation sequencing and mutation-specific platforms in clinical practice.
Hinrichs JW; van Blokland WT; Moons MJ; Radersma RD; Radersma-van Loon JH; de Voijs CM; Rappel SB; Koudijs MJ; Besselink NJ; Willems SM; de Weger RA
Am J Clin Pathol; 2015 Apr; 143(4):573-8. PubMed ID: 25780010
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Pre-Analytic Factors Affecting the Success of Clinical Next-Generation Sequencing of Solid Organ Malignancies.
Chen H; Luthra R; Goswami RS; Singh RR; Roy-Chowdhuri S
Cancers (Basel); 2015 Aug; 7(3):1699-715. PubMed ID: 26343728
[TBL] [Abstract][Full Text] [Related]
20. Quality control material for the detection of somatic mutations in fixed clinical specimens by next-generation sequencing.
Dumur CI; Almenara JA; Powers CN; Ferreira-Gonzalez A
Diagn Pathol; 2015 Sep; 10():169. PubMed ID: 26376646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
